AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEUREN PHARMACEUTICALS LTD

12.590

+0.1601.29%

Volume:1.20M

Turnover:15.06M

Market Cap:1.60B

PE:11.59

High:12.730

Open:12.600

Low:12.265

Close:12.430

Loading ...

Overview Company News Filings

2 ASX 200 pharmaceutical shares surging on big US news

Neuren's Neurodevelopmental Disorder Drug Candidate Receives US FDA Fast Track Designation; Shares Rise 5%

MT Newswires Live

Neuren Pharmaceuticals Ltd - Fast Track Granted by FDA for Nnz-2591 in Pitt Hopkins

THOMSON REUTERS

Neuren Pharmaceuticals Receives Share of Proceeds From Rare Pediatric Disease Priority Review Voucher Sale

MT Newswires Live

BRIEF-Neuren Pharmaceuticals Says Type C Meeting Granted By US FDA

Neuren set for FDA talks on trial to treat developmental genetic disorders

The Market Herald

Neuren Pharmaceuticals Gets Type C Meeting With FDA for Neurodevelopmental Disorder Drug Candidate

MT Newswires Live

Neuren Pharmaceuticals Ltd - Type C Meeting Granted by US FDA for Phelan-Mcdermid Syndrome

THOMSON REUTERS

A Look At The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Simply Wall St.

Now small investors on the ASX can pull off ‘The Big Short’

Neuren Pharmaceuticals Limited's (ASX:NEU) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Simply Wall St.

Here are the top 10 ASX 200 shares today

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Is Well Worth Watching

Simply Wall St.

ASX Market Close: IT stocks drag index lower | January 15, 2025

The Market Herald

Why did this $1.4 billion ASX 200 healthcare stock just dive 9%?

Why CAR Group, Myer, Neuren, and Yancoal shares are falling today

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NEU.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEU.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":12.59,"timestamp":1741237920000,"preClose":12.43,"halted":0,"volume":1198634,"delay":0,"changeRate":0.012872,"change":0.16,"floatShares":110014206,"shares":127012624,"eps":1.086099,"lyrEps":1.111713,"pbRate":4.39,"amount":15058600,"amplitude":0.037409,"volumeRatio":1.467186,"dividePrice":0,"prevYearClose":12.5,"fiveDayClose":14.2,"twentyDayClose":13.93},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":110014206,"roa":"34.05%","roe":"49.92%","lyrEps":1.111713,"volumeRatio":1.467186,"shares":127012624,"dividePrice":0,"high":12.73,"amplitude":0.037409,"preClose":12.43,"low":12.265,"week52Low":10.9,"pbRate":"4.39","psRate":"7.37","week52High":24,"institutionHeld":0,"latestPrice":12.59,"eps":1.086099,"divideRate":0,"volume":1198634,"delay":0,"ttmEps":1.086099,"open":12.6,"prevYearClose":12.5,"prevWeekClose":13.23,"prevMonthClose":13.23,"prevQuarterClose":12.5,"fiveDayClose":14.2,"twentyDayClose":13.93,"sixtyDayClose":12.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2512476511","title":"2 ASX 200 pharmaceutical shares surging on big US news","url":"https://stock-news.laohu8.com/highlight/detail?id=2512476511","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512476511?lang=en_us&edition=fundamental","pubTime":"2025-02-19 12:02","pubTimestamp":1739937730,"startTime":"0","endTime":"0","summary":"The market may be heading lower today but that hasn't stopped two ASX 200 pharmaceutical shares from charging higher. Let's find out what big news out of the United States is giving them a big boost t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/19/2-asx-200-pharmaceutical-shares-surging-on-big-us-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7096","BCR","CU6.AU","BK7508","NEU.AU"],"gpt_icon":1},{"id":"2512144253","title":"Neuren's Neurodevelopmental Disorder Drug Candidate Receives US FDA Fast Track Designation; Shares Rise 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512144253","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512144253?lang=en_us&edition=fundamental","pubTime":"2025-02-19 11:50","pubTimestamp":1739937010,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said that the US Food and Drug Administration  granted fast track designation to its drug candidate NNZ-2591 used for the potential treatment of Pitt Hopkins syndrome , according to a Tuesday filing with the Australian bourse.PTHS is a rare neurodevelopmental disorder with no approved treatment, the filing said.Shares of the company rose past 5% in recent Wednesday trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BYQQ9H92.USD","FAST","BK4104","BK4588","BK7096","BK7508","NEU.AU","IE00B5TLWC47.USD","BK4567","IE00BFXG0V08.USD","BK4585"],"gpt_icon":0},{"id":"2512630143","title":"Neuren Pharmaceuticals Ltd - Fast Track Granted by FDA for Nnz-2591 in Pitt Hopkins","url":"https://stock-news.laohu8.com/highlight/detail?id=2512630143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512630143?lang=en_us&edition=fundamental","pubTime":"2025-02-19 10:00","pubTimestamp":1739930434,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nFWN3P91AR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","NEU.AU"],"gpt_icon":0},{"id":"2509753856","title":"Neuren Pharmaceuticals Receives Share of Proceeds From Rare Pediatric Disease Priority Review Voucher Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2509753856","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509753856?lang=en_us&edition=fundamental","pubTime":"2025-02-07 10:02","pubTimestamp":1738893755,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  received its one-third share of proceeds from Nasdaq-listed partner Acadia Pharmaceuticals' sale of the rare pediatric disease priority review voucher for $150 million in December 2024, according to a Friday filing with the Australian bourse.The voucher was granted by the US Food and Drug Administration after the approval of Daybue for the treatment of Rett syndrome, the filing said.Rett syndrome is a genetic disorder characterized by loss of mobility in the hands as development slows down.The company is entitled to one-third of the proceeds under its license agreement with Acadia, per the filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","NEU.AU","BK7508"],"gpt_icon":0},{"id":"2509737674","title":"BRIEF-Neuren Pharmaceuticals Says Type C Meeting Granted By US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2509737674","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509737674?lang=en_us&edition=fundamental","pubTime":"2025-02-07 09:25","pubTimestamp":1738891519,"startTime":"0","endTime":"0","summary":"BRIEF-Neuren Pharmaceuticals Says Type C Meeting Granted By US FDAFeb 7 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX:TYPE C MEETING GRANTED BY US FDA FOR PHELAN-MCDERMID SYNDROMEFurther company coverage: NEU.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nFWN3OX1VE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NEU.AU","BK7508"],"gpt_icon":0},{"id":"2509182750","title":"Neuren set for FDA talks on trial to treat developmental genetic disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2509182750","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509182750?lang=en_us&edition=fundamental","pubTime":"2025-02-07 07:17","pubTimestamp":1738883820,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  has been granted the chance to talk to the U.S. Food and Drug Administration  about some of the positive indicators that may be expected from its upcoming Phase 3 clinical trial program for a drug to treat multiple childhood genetic conditions.The FDA has granted Neuren a Type C meeting – set for early April 2025 – to explore the efficacy endpoints of the trial program for candidate NNZ-2591.This comes after a Type B End of Phase 2 meeting with the government agency, in which key features of the trial were discussed and agreed to.NNZ-2591 is the company’s second drug candidate, which is in development with a focus on treating some neurodevelopmental disorders. During the Phase 2 clinical trial, it revealed positive results regarding Phelan-McDermid syndrome, Pitt-Hopkins syndrome, and Angelman syndrome.The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/neuren-set-for-fda-talks-on-trial-to-treat-developmental-genetic-disorders-2025-02-07/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7508","BK7096","NEU.AU"],"gpt_icon":0},{"id":"2509273327","title":"Neuren Pharmaceuticals Gets Type C Meeting With FDA for Neurodevelopmental Disorder Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2509273327","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509273327?lang=en_us&edition=fundamental","pubTime":"2025-02-07 07:10","pubTimestamp":1738883406,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  was granted a type C Meeting with the US Food and Drug Administration to discuss the primary efficacy endpoints of its phase 3 clinical trial program for a neurodevelopmental disorder drug candidate, the company said in a Friday Australian bourse filing.The drug candidate, NNZ-2591, is in development for multiple neurodevelopmental disorders and achieved positive results in phase 2 clinical trials in Phelan-McDermid syndrome, Pitt-Hopkins syndrome, and Angelman syndrome, per the filing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","NEU.AU","BK7508"],"gpt_icon":0},{"id":"2509781472","title":"Neuren Pharmaceuticals Ltd -  Type C Meeting Granted by US FDA for Phelan-Mcdermid Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2509781472","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509781472?lang=en_us&edition=fundamental","pubTime":"2025-02-07 05:15","pubTimestamp":1738876531,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nFWN3OX1VE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","BK7508","NEU.AU"],"gpt_icon":0},{"id":"2509458992","title":"A Look At The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2509458992","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509458992?lang=en_us&edition=fundamental","pubTime":"2025-02-06 11:35","pubTimestamp":1738812902,"startTime":"0","endTime":"0","summary":"Key Insights The projected fair value for Neuren Pharmaceuticals is AU$13.55 based on 2 Stage Free Cash Flow to Equity...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/a-look-at-the-fair-value-of-neuren-pharmaceuticals-limited-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["FCF","NEU.AU","BK4211","BK4100","BK7508","BK4109","TV","DCF","BK7096","NEU"],"gpt_icon":0},{"id":"2508154456","title":"Now small investors on the ASX can pull off ‘The Big Short’","url":"https://stock-news.laohu8.com/highlight/detail?id=2508154456","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508154456?lang=en_us&edition=fundamental","pubTime":"2025-02-03 07:39","pubTimestamp":1738539553,"startTime":"0","endTime":"0","summary":"One of the greatest recent films on share markets was The Big Short which was released in 2015.Starring Steve Carell, it did a fairly good job of explaining how shorting works and in particular how gathering information on the sort of junk property loans that were then being written in the US and collected together in highly rated collateralised debt obligations  helped to bring about the global financial crisis.It also showed how investors such as Michael Burry  and Mark Baum  could dramatically profit from shorting stocks – making money by selling shares and buying them back later at a cheaper price.One potential answer has arrived in the form of a new exchange-traded fund that will actively identify and short ASX-listed companies.Developed by VanEck and known as the VanEck Australian Long Short Complex ETF , the aim of what is effectively a listed hedge fund offering without the high initial investment hurdle is to outperform the ASX 200 by selecting a concentrated portfolio of what","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/The-Big-Short-ASX-ALFA-VanEck.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/The-Big-Short-ASX-ALFA-VanEck.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/small-investors-asx-can-pull-off-the-big-short/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK4588","BK7508","ALFA.AU","FDN","BK7001","JBH.AU","NEU.AU","BK4585","BK7096","ALF.AU","BK4550"],"gpt_icon":0},{"id":"2505758190","title":"Neuren Pharmaceuticals Limited's (ASX:NEU) Stock's On An Uptrend: Are Strong Financials Guiding The Market?","url":"https://stock-news.laohu8.com/highlight/detail?id=2505758190","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505758190?lang=en_us&edition=fundamental","pubTime":"2025-01-22 09:02","pubTimestamp":1737507736,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals'  stock is up by a considerable 13% over the past week. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. Particularly, we will be paying attention to Neuren Pharmaceuticals'  ROE today.Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders.Return on Equity = Net Profit  ÷ Shareholders' Equity. So, based on the above formula, the ROE for Neuren Pharmaceuticals is:. First thing first, we like that Neuren Pharmaceuticals has an impressive ROE. Additionally, the company's ROE is higher compared to the industry average of 13% which is quite remarkable. Under the circumstances, Neuren Pharmaceuticals' considerable five year net income growth of 81% was to be expected.Neuren Pharmaceuticals doesn't pay","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neuren-pharmaceuticals-limiteds-asx-neu-010216939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7096","BK4109","NEU.AU","NEU","BK7508"],"gpt_icon":0},{"id":"2503324079","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2503324079","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503324079?lang=en_us&edition=fundamental","pubTime":"2025-01-16 14:00","pubTimestamp":1737007202,"startTime":"0","endTime":"0","summary":"It was a jubilant Thursday session for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares today, giving investors some much-needed relief. After a shaky week, the ASX 200 wasn't holding back today a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/16/here-are-the-top-10-asx-200-shares-today-565/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7142","BK7093","BK7078","BK7096","BK7044","CTD.AU","BK7062","BK7104","BK7506","BK7070","XJO.AU","ZIP.AU","BK7161","EMR.AU","RMS.AU","BK7125","PNI.AU","KLS.AU","TAH.AU","KAR.AU","NEU.AU","JHX.AU","BK7508"],"gpt_icon":0},{"id":"2503689604","title":"Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Is Well Worth Watching","url":"https://stock-news.laohu8.com/highlight/detail?id=2503689604","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503689604?lang=en_us&edition=fundamental","pubTime":"2025-01-16 04:00","pubTimestamp":1736971232,"startTime":"0","endTime":"0","summary":"Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/heres-why-we-think-neuren-pharmaceuticals-asxneu-is-well-wor","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU.AU","BK7508","NEU","BK7096","BK4109","EBIT"],"gpt_icon":0},{"id":"2503661411","title":"ASX Market Close: IT stocks drag index lower | January 15, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503661411","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503661411?lang=en_us&edition=fundamental","pubTime":"2025-01-15 14:01","pubTimestamp":1736920860,"startTime":"0","endTime":"0","summary":"The ASX200 closed down 0.22% at 8,213 points.The local bourse gave up early gains and slipped into the red in afternoon trade, and did not return to positive territory.The Discretionary sector was the best performer, up 0.2%, followed by Real Estate, 0.13%. IT was the biggest loser, down 1.25%, followed by Telecommunication, down 1.2% and Industrials, down 0.65%.Gold Mountain closed up 50% after announcing drill targets for its Salinas II Project in Brazil.D3 Energyfinished the session up 23.1% on results from initial production testing from its major borehole in South Africa’s Free State Province. The test reported an average gas flow rate of 102,000 standard cubic feet per day over the first seven days.Arafura Rare Earths closed up 17.4% after further government support for its Nolans project with the signing of a binding term sheet for $200M with the NRFC. The company says the receipt of the convertible notes is a “key milestone” in its strategy of securing government seeded funds.H","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-it-stocks-drag-index-lower-january-15-2025-2025-01-15/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7511","BK4585","GMN.AU","BK7508","ARU.AU","BK7095","TLS.AU","BK4215","NEU.AU","HRZ.AU","BK7096","BK7142","BK4588","BK7042","MAA","D3E.AU","BK7104"],"gpt_icon":0},{"id":"2503654658","title":"Why did this $1.4 billion ASX 200 healthcare stock just dive 9%?","url":"https://stock-news.laohu8.com/highlight/detail?id=2503654658","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503654658?lang=en_us&edition=fundamental","pubTime":"2025-01-15 11:21","pubTimestamp":1736911289,"startTime":"0","endTime":"0","summary":"After a strong start to the morning's trade, things don't look so upbeat for the S&P/ASX 200 Index  this afternoon. At the time of writing, the ASX 200 has given up most of its early lead today, and is sitting pretty much flat at 8,226 points. But let's talk about one ASX 200 healthcare stock that is plunging in value.That ASX 200 healthcare stock is none other than Neuren Pharmaceuticals Ltd .Yesterday, Neuren shares closed at a flat $12 each. This morning, those same shares opened at $12.03 but quickly started dropping. At the time of writing, the ASX 200 healthcare stock has lost a horrid 8.83% and is down to just $10.94 a share. That's after going as low as $10.90 this afternoon.Well, it appears that this steep sell-off is a consequence of an ASX announcement Neuren made to investors this morning just before market open.After today's share price plunge, this ASX 200 healthcare stock is down a painful 53.6% over the past 12 months. Investors will no doubt hope for a turnaround over ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/15/why-did-this-1-4-billion-asx-200-healthcare-stock-just-dive-9/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7096","BK7508","XJO.AU","NEU.AU"],"gpt_icon":0},{"id":"2503650118","title":"Why CAR Group, Myer, Neuren, and Yancoal shares are falling today","url":"https://stock-news.laohu8.com/highlight/detail?id=2503650118","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503650118?lang=en_us&edition=fundamental","pubTime":"2025-01-15 11:12","pubTimestamp":1736910744,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index(ASX: XJO) is running out of steam and fighting hard to stay in positive territory. In afternoon trade, the benchmark index is up slightly to 8,230.9 points. Four ASX shares that a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/15/why-car-group-myer-neuren-and-yancoal-shares-are-falling-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4215","BK7096","BK7508","CAR.AU","BK7153","BK7002","LU2065171311.SGD","YAL.AU","BK4588","NEU.AU","BK7509","MAA","BK7029","BK7083","BK4139","BK7503","LU2065170008.USD","MYR.AU","LU2065171402.SGD","CAR","XJO.AU","LU2065169927.USD","ACAD","BK4585"],"gpt_icon":0}],"pageSize":16,"totalPage":7,"pageCount":2,"totalSize":106}]}}